{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071387","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.287240+00:00","generated_at":"2026-05-21T08:58:51.674856+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enliven Q1 net loss $28.5M; ELVN-001 44% MMR rate at 24 weeks, cash $290M","bullets":["Net loss of $28.5M for Q1 2025 vs $22.7M Q1 2024; R&D expenses $24.9M.","Cash, equivalents and marketable securities $289.6M; runway into late 2027.","ELVN-001 Phase 1 ENABLE: 44% (16/36) cumulative MMR by 24 weeks, well-tolerated, 74 patients.","Strategic alternatives for ELVN-002 program; not pursued beyond 2025 to extend cash runway.","Updated ELVN-001 data to be presented at EHA Congress in June; webcast June 13."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071387","json":"https://secwatch.observer/filing/0000950170-25-071387.json","markdown":"https://secwatch.observer/filing/0000950170-25-071387.md","text":"https://secwatch.observer/filing/0000950170-25-071387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/0000950170-25-071387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000095017025071387/elvn-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:58:51.674856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}